跳至主要内容
临床试验/EUCTR2008-006802-40-NO
EUCTR2008-006802-40-NO进行中(未招募)不适用

A PHASE II STUDY WITH OXALIPLATIN + 5FU + CETUXIMAB AND RADIOTHERAPY FOR TREATMENT OF NON-RESECTABLE, LOCALLY ADVANCED BUT NOT METASTATIC CANCER OF OESOPHAGUS OR THE CARDIA REGION - LERFOX-C

Akademiska University Hospital0 个研究点目标入组 90 人开始时间: 2012年6月28日最近更新:
适应症
相关药物

试验速览

阶段
不适用
状态
进行中(未招募)
发起方
入组人数
90

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
All

入选标准

  • Histologically verified squamous cell carcinoma or adenocarcinoma of the oesophagus or cardia (Siewert I-II)
  • Performance status (WHO) 0-2, age 18-80 y
  • Locally advanced disease non-resectable (T4 N0-N3, M0) or disease which is not operable for any other reason (T2/T3 N0-N3, M0)
  • Adequate hematological, liver and renal function
  • Written informed consent
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range
  • F.1.3 Elderly (>=65 years) yes
  • F.1.3.1 Number of subjects for this age range

排除标准

  • Distant metastases
  • Prior chemotherapy or radiotherapy for oesophageal ca or ca of the cardia region
  • Symptomatic peripheral neuropathy equal to or greater than NCI grade 2
  • Other concomitant serious illness or medical condition that would not permit the patient to complete the study treatment or sign the informed concent
  • Myocardial infarction within 6 months prior to study entry
  • Second primary malignancy (except in situ carcinoma of the cervix or adequately treated basal cell carcinoma of the skin) unless treated, in remission and off active treatment for greater than 5 years

研究者

发起方
Akademiska University Hospital

相似试验